Eagle Bay Advisors LLC Coherus Bio Sciences, Inc. Transaction History

Eagle Bay Advisors LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 08, 2024	SELL	$2.02 - $3.14 $78 - $122	-39 Reduced 56.52%	30 $0
Q4 2023 Feb 08, 2024	SELL	$1.59 - $3.85 $8,210 - $19,881	-5,164 Reduced 98.68%	69 $0
Q3 2023 Nov 13, 2023	BUY	$3.74 - $5.45 $13,946 - $20,323	3,729 Added 247.94%	5,233 $19,000
Q2 2023 Aug 10, 2023	SELL	$3.79 - $8.3 $10,354 - $22,675	-2,732 Reduced 64.49%	1,504 $6,000
Q1 2023 Apr 24, 2023	BUY	$5.89 - $10.52 $17,723 - $31,654	3,009 Added 245.23%	4,236 $28,000
Q4 2022 Jan 26, 2023	SELL	$5.69 - $10.07 $15,789 - $27,944	-2,775 Reduced 69.34%	1,227 $0
Q3 2022 Nov 22, 2022	BUY	$7.17 - $13.87 $795 - $1,539	111 Added 2.85%	4,002 $39,000
Q2 2022 Aug 19, 2022	BUY	$5.86 - $13.23 $13,143 - $29,674	2,243 Added 136.1%	3,891 $28.2 Million
Q1 2022 May 11, 2022	SELL	$10.92 - $16.41 $5,154 - $7,745	-472 Reduced 22.26%	1,648 $21,000
Q4 2021 Jan 21, 2022	BUY	$15.81 - $18.99 $5,596 - $6,722	354 Added 20.05%	2,120 $34,000
Q3 2021 Nov 12, 2021	SELL	$12.68 - $17.79 $1,965 - $2,757	-155 Reduced 8.07%	1,766 $28,000
Q2 2021 Jul 30, 2021	BUY	$12.95 - $15.41 $24,876 - $29,602	1,921 New	1,921 $28,000

135

77.9M

40.7K

50.1K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $115M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Eagle Bay Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Eagle Bay Advisors LLC with notifications on news.